Hepatitis C New D...
Follow
Find
6.3K views | +14 today
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

A Novel Promising Therapeutic Option Against HCV... [Curr Med Chem. 2013] - PubMed - NCBI

PubMed comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries | Gilead

Gilead Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries | Gilead | Hepatitis C New Drugs Review | Scoop.it

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. – to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.

The countries within the agreement account for more than 100 million people living with hepatitis C, representing 54% of the total global infected population.

 

Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible. The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

Sofosbuvir was approved under the trade name Sovaldi® by the U.S. Food and Drug

 

Krishan Maggon 's insight:

Sofosbuvir was approved under the trade name Sovaldi® by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Commission in January 2014. The FDA and the European Medicines Agency are currently reviewing the company’s applications for a single tablet regimen of ledipasvir/sofosbuvir; it is an investigational agent and its safety and efficacy have not been established.

For a fact sheet on the agreement, visit www.gilead.com.

- See more at: http://gilead.com/news/press-releases/2014/9/gilead-announces-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments-in-developing-countries#sthash.Ec36Ep8F.dpuf

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients - HCPLive

Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients - HCPLive | Hepatitis C New Drugs Review | Scoop.it
Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients HCPLive Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, a study...
Krishan Maggon 's insight:

Alcohol, drug addiction and lack of physical exercise impairs liver functions.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New drug could eliminate hepatitis C in 15 years - The Pharmaceutical Journal

New drug could eliminate hepatitis C in 15 years - The Pharmaceutical Journal | Hepatitis C New Drugs Review | Scoop.it
The Pharmaceutical Journal
New drug could eliminate hepatitis C in 15 years
The Pharmaceutical Journal
Daclatasvir is licensed for the treatment of HCV in combination with other medicines.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Zacks.com

Bidness ETC Gilead Down on Likely Sovaldi Generic Deal in Poor Nations Zacks.com According to the report, Gilead is very close to completing the licensing deal which will permit generic players to make Sovaldi and one more candidate combining...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Report: Innovation in Hepatitis C Treatment

New Report: Innovation in Hepatitis C Treatment | Hepatitis C New Drugs Review | Scoop.it
Today, the California Healthcare Institute released a report on the public health impact of Hepatitis C and the potential of groundbreaking new treatments to (New Report: Innovation in Hepatitis C Treatment | BIOtechNow
Krishan Maggon 's insight:

Full report  pdf

 

http://www.chi.org/wp-content/uploads/2014/07/Innovation-in-Hep-C-Treatment-New-Opportunity-for-Action.pdf

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Close to Sending $84,000 Drug to Poor Countries

Gilead Close to Sending $84,000 Drug to Poor Countries | Hepatitis C New Drugs Review | Scoop.it
Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.
Krishan Maggon 's insight:

Gilead has taken the lead to license  its AIDS and HCV drugs to generic manufacturers in poor countries at lower prices.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Testing for hepatitis B virus and HIV in patients with chronic hepatitis C: Screening performance and outcome, Scandinavian Journal of Infectious Diseases, Informa Healthcare

Testing for hepatitis B virus and HIV in patients with chronic hepatitis C: Screening performance and outcome, Scandinavian Journal of Infectious Diseases, Informa Healthcare | Hepatitis C New Drugs Review | Scoop.it

Background: Patients infected with hepatitis C virus (HCV) and co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) are at increased risk for progression of liver disease. The aim of this study was to assess HBV and HIV screening performance and outcome in HCV patients followed at a Danish university hospital and affiliated regional outpatient clinics. Methods: HBV and HIV serology data were extracted from a quality assurance database for the assessment of screening performance in patients diagnosed with chronic HCV infection during the period 1 January 1996 to 31 December 2011. Patients with incomplete and missing serology data had complementary serology tests performed to assess the prevalence of HBV and HIV co-infection and HBV immune status. Results: Among 624 HCV patients, 10 (2%) were co-infected with chronic HBV and 32 (5%) with HIV. Approximately half of the cohort were non-immune to HBV or had an unknown HBV serology status. Serology results consistent with resolved infection and HBV vaccination were found in 209 (33%) and 65 (10%) patients, respectively. During the 16-y observation period, HBV and HIV screening coverage at HCV diagnosis increased from 23% to 92% and from 38% to 80%, respectively. Conclusion: Despite improvements throughout the study period, HBV and HIV serology screening remained incomplete. The majority of patients were either HBV non-immune or had an unknown HBV serology status. These findings thus call for a more proactive screening approach as well as an improved HBV vaccination strategy for patients with chronic HCV infection.


Read More: http://informahealthcare.com/doi/abs/10.3109/00365548.2014.929734

Krishan Maggon 's insight:
Testing for hepatitis B virus and HIV in patients with chronic hepatitis C: Screening performance and outcome

 

Posted online on August 19, 2014. (doi:10.3109/00365548.2014.929734)Maria Bolther1, Lars Skov Dalgaard1, Lena Hagelskjaer Kristensen2, Britta Damgaard Tarp3 & Søren Jensen-Fangel11From the Department of Infectious Diseases, Aarhus University Hospital2Department of Internal Medicine, Infectious Diseases Unit, Viborg Regional Hospital3Diagnostic Centre, Silkeborg Regional Hospital, DenmarkCorrespondence: M. Bolther, Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. Tel: + 45 7845 2846. E-mail: mariabolther@gmail.com




Read More: http://informahealthcare.com/doi/abs/10.3109/00365548.2014.929734

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Minimum costs to produce Hepatitis C Direct Acting Antivirals - hepCoalition

Minimum costs to produce Hepatitis C Direct Acting Antivirals - hepCoalition | Hepatitis C New Drugs Review | Scoop.it
Minimum costs of treatment and diagnostics to cure hepatitis C virus (HCV) were estimated at US$177-354 per person without genotyping, and (...) (RT @hepCoalition: Minimum costs (177 $US) to produce #HCV Direct Acting Antivirals (#sofosbuvir + #daclastavir)...
Krishan Maggon 's insight:

Minimum costs of treatment and diagnostics to cure hepatitis C virus (HCV) were estimated at US$177 per person without genotyping, and US$267 per person with genotyping. 
These costs assume that large-scale treatment programmes can be established for Hepatitis C, similar to those implemented for HIV/AIDS. This low cost treatment package could make universal access to HCV treatment in lower resource settings a realistic goal.


If HCV drugs are produced in India under license with single digit 5-7% royalties for the originating company, these costs can come down.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir - Donaldson - Hepatology - Wiley Online Library

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir - Donaldson - Hepatology - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Even #sofosbuvir may give #resistance to #hepatitisC #hepC http://t.co/rSrzIRndMC

 

ABSTRACT

Sofosbuvir (Sovaldi™, SOF) is a nucleotide analog prodrug that targets the hepatitis C virus (HCV) NS5B polymerase and inhibits viral replication. High sustained virologic response rates are achieved when SOF is used in combination with ribavirin with or without pegylated interferon in subjects with chronic HCV infection. Potential mechanisms of HCV resistance to SOF and other nucleos(t)ide analog NS5B polymerase inhibitors are not well understood. SOF was the first FDA-approved antiviral drug for which genotypic resistance analyses were based almost entirely on next generation sequencing (NGS), an emerging technology that lacks a standard data analysis pipeline. The FDA Division of Antiviral Products developed an NGS analysis pipeline and performed independent analyses of NGS data from 5 SOF clinical trials. Additionally, structural bioinformatics approaches were used to characterize potential resistance-associated substitutions. Using protocols we developed, independent analyses of the NGS data reproduced results that were comparable to those reported by Gilead Sciences, Inc. Low frequency treatment-emergent substitutions occurring at conserved NS5B amino acid positions in subjects who experienced virologic failure were also noted and further evaluated. The NS5B substitutions, L159F (sometimes in combination with L320F or C316N) and V321A, emerged in 2.2-4.4% of subjects who failed SOF treatment across clinical trials. Moreover, baseline polymorphisms at position 316 were potentially associated with reduced response rates in HCV genotype 1b subjects. Analyses of these variants modelled in NS5B crystal structures indicated that all 4 substitutions could feasibly impact SOF anti-HCV activity. Conclusion: SOF has a high barrier to resistance; however, low frequency NS5B substitutions associated with treatment failure were identified that may contribute to resistance of this important drug for chronic HCV infection. (Hepatology 2014;)

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agents

Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agents | Hepatitis C New Drugs Review | Scoop.it

Direct acting antivirals have significantly improved treatment outcomes in chronic hepatitis C (CHC), but side effects, drug resistance and cost mean that better treatments are still needed. Lipid metabolism is closely linked with hepatitis C virus (HCV) replication and endocannabinoids are major regulators of lipid homeostasis. The cannabinoid 1 (CB1) receptor mediates these effects in the liver. We have previously shown up-regulation of CB1 receptors in the livers of patients with CHC, and in a HCV cell culture model. Here we investigated whether CB1 blockade inhibits HCV replication. The antiviral effect of a CB1 antagonist, AM251 was examined in the JFH1 cell culture and subgenomic replicon models. The effects on the expression of genes involved in lipid metabolism were also measured. CB1 shRNA was used to confirm that the effects were specific for the cannabinoid receptor. Treatment with AM251 strongly inhibited HCV RNA (~70%), viral protein (~80%), the production of new virus particles (~70%), and virus infectivity (~90%). As expected, AM251 reduced the expression of pro-lipogenic genes (SREBP-1c, FASN, SCD1 and ACC1) and stimulated genes promoting lipid oxidation (CPT1 and PPARα). This effect was mediated by AMPK. Stable CB1 knockdown of cells infected with HCV showed reduced levels of HCV RNA, compared with controls. Reduced CB1 signalling inhibits HCV replication using either pharmacological inhibitors or CB1 shRNA. This may be due, at least in part, to reduced lipogenesis, mediated by AMPK activation. We suggest that CB1 antagonists may represent an entirely new class of drugs with activity against HCV.

Krishan Maggon 's insight:
Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host targeting agentsMahsa Shahidi1, Enoch S.E Tay1, Scott A. Read1,Mehdi Ramezani-Moghadam1, Kazuaki Chayama2, Jacob George1 andMark W. Douglas1,3

+Author Affiliations

1 Storr Liver Unit, University of Sydney at Westmead Hospital, Australia;2 Department of Gastroenterology and Metabolism, Hiroshima University, Japan↵3 E-mail: mark.douglas@sydney.edu.auReceived 27 April 2014.Accepted 21 July 2014.Published online ahead of print July 22, 2014, doi:10.1099/vir.0.067231-0J Gen Virol July 2014vir.0.067231-0
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Achillion Pharmaceuticals, Inc. (ACHN): Big Potential and Attractive Covered ... - iStockAnalyst (press release)

Achillion Pharmaceuticals, Inc. (ACHN): Big Potential and Attractive Covered ... - iStockAnalyst (press release) | Hepatitis C New Drugs Review | Scoop.it
iStockAnalyst (press release)
Achillion Pharmaceuticals, Inc. (ACHN): Big Potential and Attractive Covered ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead: NICE OK for Solvadi and patent win vs Roche

Gilead: NICE OK for Solvadi and patent win vs Roche | Hepatitis C New Drugs Review | Scoop.it
Gilead Sciences can't seem to do anything wrong. Not only has the biotech's hepatitis C treatment Sovaldi become a multibillion-dollar drug less than.
Krishan Maggon 's insight:

Gilead has already paid  back the cost of Pharmasset acquisition by reaping multibillion dollar sales of soforbuvir and increase in its market cap. NICE OK means it is available to HCV patients of NHS at 30% discount to the US price. Patent win vs Roche is a bonus

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Simeprevir Particularly Effective in Treatment-naïve and Relapsed Hepatitis C IQWiG - HCPLive

Simeprevir Particularly Effective in Treatment-naïve and Relapsed Hepatitis C IQWiG - HCPLive | Hepatitis C New Drugs Review | Scoop.it
Simeprevir Particularly Effective in Treatment-naïve and Relapsed Hepatitis C ...
Krishan Maggon 's insight:

Germany cost control agency  Institute for Quality and Efficiency in Health Care (IQWiG) 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries - Business Standard

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries - Business Standard | Hepatitis C New Drugs Review | Scoop.it
Livemint Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries Business Standard Multinational American drug maker Gilead Sciences was set to join hands with at least five Indian generic pharmaceutical companies and allow them...
Krishan Maggon 's insight:

Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient (API) rights.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

SAPPHIRE-I, II: Treatment sustained despite hyperbilirubinemia in some HCV Patients - ICAAC 2014

SAPPHIRE-I, II: Treatment sustained despite hyperbilirubinemia in some HCV Patients - ICAAC 2014 | Hepatitis C New Drugs Review | Scoop.it
SAPPHIRE-I, II: Treatment sustained despite hyperbilirubinemia in some HCV ...
Healio
...
Krishan Maggon 's insight:

Interferon free triple antiviral therapy was effective with minimal ADRs.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hep Pro | A unique hepatitis database and patient management system

Hep Pro |  A unique hepatitis database and patient management system | Hepatitis C New Drugs Review | Scoop.it
Hep-Pro is a unique database and patient management system designed to meet unprecedented clinical needs for treating and monitoring hepatitis patients.
Krishan Maggon 's insight:

A data and HCV patient management system

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Is a Cheap Hepatitis C Cure About to Go Global? - Motley Fool

Is a Cheap Hepatitis C Cure About to Go Global? - Motley Fool | Hepatitis C New Drugs Review | Scoop.it
Bidness ETC
Is a Cheap Hepatitis C Cure About to Go Global?
Krishan Maggon 's insight:

Like AIDS medicines, HCV therapy is going to be available in poor countries at discounted prices.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Infographic: Hepatitis C - Genetic Engineering & Biotechnology News

Infographic: Hepatitis C - Genetic Engineering & Biotechnology News | Hepatitis C New Drugs Review | Scoop.it
Genetic Engineering & Biotechnology News
Infographic: Hepatitis C
Genetic Engineering & Biotechnology News
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV).
more...
No comment yet.
Rescooped by Krishan Maggon from Apropos health care
Scoop.it!

GEN | Insight & Intelligence™: Why Is Everybody Picking on Sovaldi?

GEN | Insight & Intelligence™: Why Is Everybody Picking on Sovaldi? | Hepatitis C New Drugs Review | Scoop.it

The hepatitis C drug's $84,000 price tag threatens to prevent widespread use....A substantial reduction in Sovaldi price should make cost-benefit very attractive, opening up the potential market and substantially increasing dollar sales above those anticipated for the present price.


Via Greg Judd
more...
Greg Judd's curator insight, September 3, 10:04 PM

For this interested non-clinical bystander, this report is most attention-getting - but we're guessing its assertions may be found controversial by more than a few health care industry constituencies.

Scooped by Krishan Maggon
Scoop.it!

More Direct-Acting HCV Antivirals, More Controversy in Europe

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir).
Krishan Maggon 's insight:

The higher prices of new antivirals which cure over 95% of treated patients vs the actual cost of current HCV treatment.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Hope for Patients with Hepatitis C

New Hope for Patients with Hepatitis C | Hepatitis C New Drugs Review | Scoop.it
New and forthcoming medicines can halt the progression of hepatitis C and, in many cases, provide a cure.
Krishan Maggon 's insight:

PHRMA infographic about the impact of new HCV drugs. 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

EMA/EC approve Bristol-Myers Squibb Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis

 

The approval of Daklinza is supported by data from multiple studies, including an open-label, randomized study of Daklinza with sofosbuvir in genotypes 1, 2, and 3, including patients with no response to prior therapy with telaprevir or boceprevir and patients with fibrosis. Results showed that a regimen of Daklinza with sofosbuvir achieved SVR12 (sustained virologic response 12 weeks after the end of treatment; a functional cure) in 99% of treatment-naïve patients with HCV genotype 1, 100% of patients with genotype 1 who had failed treatment with either telaprevir or boceprevir, 96% of those with genotype 2 and 89% of those with genotype 3.

In addition, the regimen resulted in low rates of discontinuation (<1%) due to adverse events (AEs). The rate of serious adverse events (SAEs) was low (4.7%). The most common adverse events were fatigue, headache and nausea. Across clinical studies, Daklinza-based regimens have been generally well tolerated with low rates of discontinuation across a range of patients. Ongoing and completedDaklinza studies have included more than 5,500 patients in a variety of all-oral regimens and with the current interferon-based standard of care.

The safety of Daklinza for the treatment of hepatitis C has been demonstrated in diverse patient populations that include elderly patients, patients with advanced liver disease, post-liver transplant recipients and patients co-infected with HIV. No unique safety concerns have been identified in patients who were treated withDaklinza across clinical studies and in the early access program. Several of these studies are ongoing.

Krishan Maggon 's insight:

Daklinza, when used in combination with sofosbuvir, is an all-oral, once daily regimen that yields cure rates of up to 100%


Daklinza + sofosbuvir offers potential cure for a broad range of EU HCV patients, including those with advanced liver disease, genotype 3 and protease inhibitor failures.

 

NDA filed with FDA, under priority review, PDUFA date 30 Nov. 2014

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Resistance to hepatitis C virus protease inhibitors

Resistance to hepatitis C virus protease inhibitors | Hepatitis C New Drugs Review | Scoop.it
Highlights

 

Baseline protease inhibitor resistance is rare, with the exception of Q80K.

Emergence of resistance is common in patients who do not achieve an SVR.

Resistance pathways are dependent on drug exposure and viral genotype.

Potency and genetic barrier of regimen play major roles in inhibiting resistance.

Resistant populations tend to be replaced by wild-type virus over time.

Krishan Maggon 's insight:
Resistance to hepatitis C virus protease inhibitors ☆Tara L Kieffer , Shelley George DOI: 10.1016/j.coviro.2014.04.008
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients - Fuster - 2014 - Journal of Viral Hepatitis - Wiley Online Library

Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients - Fuster - 2014 - Journal of Viral Hepatitis - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
What Is the impact of #hepatitis C virus infection on the risk of death of alcohol-dependent patients?→http://t.co/0tqeifDmRV #HepC #HCV

 

Summary

Hepatitis C virus (HCV) infection is frequent among patients with alcohol use disorders. We aimed to analyse the impact of HCV infection on survival of patients seeking treatment for alcohol use. This was a longitudinal study in a cohort of patients who abused alcohol recruited in two detoxification units. Socio-demographic and alcohol use characteristics, liver function tests for the assessment of alcohol-related liver disease and HCV and HIV infection serologies were obtained at admission. Patients were followed until December 2008; causes of death were ascertained through clinical records and death registry. Cox models were used to analyse predictors of death. A total of 675 patients (79.7% men) were admitted; age at admission was 43.5 years (IQR: 37.9–50.2 years), duration of alcohol abuse was 18 years (IQR: 11–24 years), and median alcohol consumption was 200 g/day (IQR: 120–275 g/day). Distribution of patients according to viral infections was as follows: 75.7% without HCV or HIV infection, 14.7% HCV infection alone and 8.1% HCV/HIV coinfection. Median follow-up was 3.1 years (IQR: 1.5–5.1 years) accounting for 2,345 person-years. At the end of study, 78 patients (11.4%) had died. In the multivariate analysis, age at admission (HR = 1.71, 95%CI: 1.05–2.80), alcohol-related liver disease (HR = 3.55, 95%CI: 1.93–6.53) and HCV/HIV co-infection (HR = 3.86 95%CI: 2.10–7.11) were predictors of death. Younger patients (≤43 years) with HCV infection were more likely to die than those without viral infections (HR = 3.1, 95%CI: 1.3–7.3; P = 0.007). Among patients with alcohol-related liver disease, mortality rate was high, irrespective of viral infections. These data show that HCV infection confers a worse prognosis in patients with alcohol use disorders.

Krishan Maggon 's insight:
Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patientsD. Fuster1,2,*, A. Sanvisens1, F. Bolao3, I. Serra4, I. Rivas5, J. Tor1 andR. Muga1

Article first published online: 18 AUG 2014

DOI: 10.1111/jvh.12290

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Market cap of Achillion Pharmaceuticals up by $100 million based on a small study?

Market cap of Achillion Pharmaceuticals up by $100 million based on a small study? | Hepatitis C New Drugs Review | Scoop.it
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're.
Krishan Maggon 's insight:

Positive news about 100%  cure in only 12 patients in 8 weeks added $ 100 million to the company market cap. This is crazy and highly speculative. The results were  obtained in combination with sofosbuvir. Several other antivirals in R&D are expected to deliver similar results. 

more...
No comment yet.